Patients struggling to break dependence on opioids will soon have a cheaper treatment option available following the US Food and Drug Administration’s (FDA) decision to approve the first generic sublingual version of Suboxone (buprenorphine and naloxone).  In April 2017, the US...

The US Food and Drug Administration (FDA) and Federal Trade Commission (FTC) have turned their attention to companies illegally marketing products to help with opioid withdrawal and addiction. The agencies sent letters to the marketers and distributors of the products with warnings about their...

The US Food and Drug Administration has granted approval to Sublocade (buprenorphine extended release) for the treatment of patients with moderate to severe opioid use disorder. Shaun Thaxter, chief executive officer of Indivior, described the approval as an “important step forward for...

Scott Gottlieb, MD, US Food and Drug Administration (FDA) Commissioner, has outlined the FDA's plans to tackle the nation's opioid abuse epidemic. Speaking to the House Committee on Energy and Commerce Hearing, he described opioid addiction as the "biggest crisis facing public health...

A new formulation of the opioid oxycodone has been approved by the US Food & Drug Administration (FDA), providing doctors with a new option for treating patients in pain. RoxyBond (oxycodone hydrochloride) is the first immediate-release opioid analgesic with labeling for abuse-deterrent...